Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Liver Cirrhosis

  Free Subscription


Articles published in J Gastroenterol

Retrieve available abstracts of 24 articles:
HTML format



Single Articles


    September 2021
  1. HANAI T, Nishimura K, Miwa T, Maeda T, et al
    Usefulness of nutritional therapy recommended in the Japanese Society of Gastroenterology/Japan Society of Hepatology evidence-based clinical practice guidelines for liver cirrhosis 2020.
    J Gastroenterol. 2021 Sep 17. pii: 10.1007/s00535-021-01821.
    PubMed     Abstract available


    July 2021
  2. YOSHIJI H, Nagoshi S, Akahane T, Asaoka Y, et al
    Evidence-based clinical practice guidelines for Liver Cirrhosis 2020.
    J Gastroenterol. 2021 Jul 7. pii: 10.1007/s00535-021-01788.
    PubMed     Abstract available


    May 2021
  3. ITAKURA J, Kurosaki M, Setoyama H, Simakami T, et al
    Applicability of APRI and FIB-4 as a transition indicator of liver fibrosis in patients with chronic viral hepatitis.
    J Gastroenterol. 2021;56:470-478.
    PubMed     Abstract available


    March 2021
  4. ENOMOTO H, Nishiguchi S
    Reply to the letter by Huo et al. regarding our manuscript "The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan".
    J Gastroenterol. 2021 Mar 11. pii: 10.1007/s00535-021-01768.
    PubMed    


    February 2021
  5. ISHIKAWA T, Sasaki R, Nishimura T, Matsuda T, et al
    Splenic non-infarction volume determines a clinically significant hepatic venous pressure gradient response to partial splenic embolization in patients with cirrhosis and hypersplenism.
    J Gastroenterol. 2021 Feb 24. pii: 10.1007/s00535-021-01762.
    PubMed     Abstract available


    November 2020
  6. ENOMOTO H, Ueno Y, Hiasa Y, Nishikawa H, et al
    The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan.
    J Gastroenterol. 2020 Nov 20. pii: 10.1007/s00535-020-01748.
    PubMed     Abstract available


    October 2020
  7. TAHATA Y, Hikita H, Mochida S, Kawada N, et al
    Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study.
    J Gastroenterol. 2020 Oct 1. pii: 10.1007/s00535-020-01733.
    PubMed     Abstract available


    June 2020
  8. SAWADA Y, Shiraki M, Iwasa M, Hiraoka A, et al
    The effects of diuretic use and the presence of ascites on muscle cramps in patients with cirrhosis: a nationwide study.
    J Gastroenterol. 2020 Jun 12. pii: 10.1007/s00535-020-01694.
    PubMed     Abstract available


    May 2020
  9. SAKAIDA I, Terai S, Kurosaki M, Okada M, et al
    Real-world effectiveness and safety of tolvaptan in liver cirrhosis patients with hepatic edema: results from a post-marketing surveillance study (START study).
    J Gastroenterol. 2020 May 9. pii: 10.1007/s00535-020-01691.
    PubMed     Abstract available


    February 2020
  10. TAKEHARA T, Chayama K, Kurosaki M, Yatsuhashi H, et al
    JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study.
    J Gastroenterol. 2020 Feb 17. pii: 10.1007/s00535-020-01672.
    PubMed     Abstract available


    January 2020
  11. KAJI K, Yoshiji H
    Can portal hypertension and hepatic decompensation be predicted?
    J Gastroenterol. 2020 Jan 21. pii: 10.1007/s00535-020-01669.
    PubMed    


    December 2019
  12. SCHWARZER R, Reiberger T, Mandorfer M, Kivaranovic D, et al
    The von Willebrand Factor antigen to platelet ratio (VITRO) score predicts hepatic decompensation and mortality in cirrhosis.
    J Gastroenterol. 2019 Dec 12. pii: 10.1007/s00535-019-01656.
    PubMed     Abstract available


    November 2019
  13. ENOMOTO H, Ueno Y, Hiasa Y, Nishikawa H, et al
    Transition in the etiology of liver cirrhosis in Japan: a nationwide survey.
    J Gastroenterol. 2019 Nov 25. pii: 10.1007/s00535-019-01645.
    PubMed     Abstract available


    October 2019
  14. ENOOKU K, Tsutsumi T, Kondo M, Fujiwara N, et al
    Hepatic FATP5 expression is associated with histological progression and loss of hepatic fat in NAFLD patients.
    J Gastroenterol. 2019 Oct 10. pii: 10.1007/s00535-019-01633.
    PubMed     Abstract available


    September 2019
  15. KIM D, Kim W, Joo SK, Han J, et al
    Association between body size-metabolic phenotype and nonalcoholic steatohepatitis and significant fibrosis.
    J Gastroenterol. 2019 Sep 18. pii: 10.1007/s00535-019-01628.
    PubMed     Abstract available


    July 2019
  16. SHIMADA S, Tanaka S
    A new era for understanding genetic evolution of multistep carcinogenesis.
    J Gastroenterol. 2019;54:667-668.
    PubMed     Abstract available


    June 2019
  17. MIZUNO K, Toyoda H, Yasuda S, Tada T, et al
    The course of elderly patients with persistent hepatitis C virus infection without hepatocellular carcinoma.
    J Gastroenterol. 2019 Jun 3. pii: 10.1007/s00535-019-01595.
    PubMed     Abstract available


    March 2019
  18. SUMIDA Y, Yoneda M, Okanoue T
    Is the grade of ballooned hepatocytes a significant risk factor for rapid progression of hepatic fibrosis in patients with NAFLD?
    J Gastroenterol. 2019 Mar 26. pii: 10.1007/s00535-019-01573.
    PubMed    


  19. SEZAKI H, Suzuki F, Hosaka T, Fujiyama S, et al
    Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections.
    J Gastroenterol. 2019 Mar 22. pii: 10.1007/s00535-019-01575.
    PubMed     Abstract available


    February 2019
  20. SUDA G, Hasebe C, Abe M, Kurosaki M, et al
    Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection.
    J Gastroenterol. 2019 Feb 18. pii: 10.1007/s00535-019-01556.
    PubMed     Abstract available


  21. SHIRABE K, Bekki Y, Gantumur D, Araki K, et al
    Response to the letter by Dr. Naoya Yamada, and Dr. Koichi Mizuta regarding our manuscript: "Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis".
    J Gastroenterol. 2019;54:206-207.
    PubMed    


  22. KANNO M, Kawaguchi K, Honda M, Horii R, et al
    Serum aldo-keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis.
    J Gastroenterol. 2019 Feb 1. pii: 10.1007/s00535-019-01551.
    PubMed     Abstract available


    November 2018
  23. YAMADA N, Mizuta K
    Advanced assessment of serum Mac-2 binding protein glycosylation isomer in patients with biliary atresia.
    J Gastroenterol. 2018 Nov 9. pii: 10.1007/s00535-018-1523.
    PubMed    


    July 2018
  24. SUDA G, Kurosaki M, Itakura J, Izumi N, et al
    Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection.
    J Gastroenterol. 2018 Jul 17. pii: 10.1007/s00535-018-1495.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Cirrhosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: